hemming& Wealth Management Inc. Acquires Shares of 2,206 Stryker Corporation $SYK

hemming& Wealth Management Inc. bought a new stake in shares of Stryker Corporation (NYSE:SYK) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 2,206 shares of the medical technology company’s stock, valued at approximately $777,000. Stryker makes up about 0.5% of hemming& Wealth Management Inc.’s portfolio, making the stock its 11th largest position.

Several other institutional investors have also modified their holdings of the business. Sankala Group LLC acquired a new stake in Stryker during the 4th quarter valued at approximately $26,000. Godfrey Financial Associates Inc. acquired a new position in shares of Stryker in the 4th quarter valued at approximately $26,000. United Financial Planning Group LLC acquired a new position in shares of Stryker in the 3rd quarter valued at approximately $27,000. Atlas Capital Advisors Inc. purchased a new position in shares of Stryker during the 4th quarter valued at approximately $27,000. Finally, DJE Kapital AG purchased a new position in shares of Stryker during the 4th quarter valued at approximately $28,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insiders Place Their Bets

In other news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the sale, the vice president owned 13,137 shares in the company, valued at $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 323,264 shares of company stock valued at $100,659,489 over the last quarter. Insiders own 4.60% of the company’s stock.

Stryker Stock Performance

Stryker stock opened at $308.62 on Friday. The company has a market cap of $118.31 billion, a PE ratio of 35.72, a P/E/G ratio of 1.97 and a beta of 0.78. The company has a fifty day moving average price of $313.81 and a two-hundred day moving average price of $341.71. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87.

Stryker (NYSE:SYK) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts expect that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio is 40.74%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SYK. Leerink Partners dropped their price target on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Citigroup reduced their price objective on shares of Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a report on Friday, May 1st. Barclays dropped their target price on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. Finally, Evercore set a $355.00 price target on shares of Stryker in a research report on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $395.33.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.